FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				01 36	ection	30(r	i) of the	investme	ent C	ompany A	ct of 1940								
Name and Address of Reporting Person* Biller Scott					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director						
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/20/2017								X	below)			below		
					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) CAMBRIDGE MA 02139														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(St	ate)	(Zip)																	
	Tab	le I -	Non-Deriv	vative	Sec	urit	ies A	cquired	, Di	sposed	of, or B	enefic	ially	Own	ed				
1. Title of Security (Instr. 3)		Date	Year) i	Execution Date,				Disposed				nd Securities Beneficially Owned		Forn (D) o	rm: Direct or irect (I)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	-	Report Transa	ed ction(s)	(inst	r. 4)	(Instr. 4)	
Common stock 03/20/2				17	17			M ⁽¹⁾		5,933	A	\$9.	05	21	,403	03 D			
Common stock			03/20/20)17				S ⁽²⁾		5,933	D	\$5	5 15		,470		D		
Common stock			03/20/20	/20/2017				M ⁽¹⁾		505	A	\$0.4	675 15		5,975 D		D		
Common stock			03/20/20	17			S ⁽²⁾		505	D	\$5	55	15	5,470 D		D			
Common stock														31	1,000			See footnote ⁽³⁾	
	Т	able												wned					
Derivative Conversion Date	Date Execu Month/Day/Year) if any		Deemed ution Date,	4. Transa Code (ction	5. Number of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3		6. Date Expiratio	exercisable and on Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)		derivative Securities Beneficial Owned Following Reported	Ownershis Form: Direct (D) or Indirect (I) (Instr.	Ownership Form: Direct (D) or Indirect (I) (Instr.	Beneficial) Ownership	
				Code	V (A)		(D)	Date Exercisal			Title	or	er						
\$0.4675	03/20/2017			M ⁽¹⁾			505	(4)		12/06/2020	Common stock	505	\$	0.00	4,969		D		
\$9.05	03/20/2017			M ⁽¹⁾			5,933	(5)		04/29/2023	Common stock	5,933	\$ \$	0.00	48,157	,	D		
	(Final Strate of	(First) SPHARMACEUTICALS Y STREET DGE MA (State) Table Courity (Instr. 3) tock tock tock tock tock tock tock toc	(First) (Middle S PHARMACEUTICALS, INCY STREET DGE MA 0213 (State) (Zip) Table I - Courity (Instr. 3) tock tock tock tock tock tock tock toc	(First) (Middle) SPHARMACEUTICALS, INC. YSTREET DGE MA 02139 (State) (Zip) Table I - Non-Derivation (Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Month/Day/Year) Table II - Derivative (e.g., p. month/Day/Year) Solution (Month/Day/Year) Solution (Month/Day/Year) Solution (Month/Day/Year)	Address of Reporting Person* Cott (First) (Middle) SPHARMACEUTICALS, INC. YSTREET Table I - Non-Derivative Curity (Instr. 3) Table I - Non-Derivative Curity (Instr. 3) Table II - Derivative Cock Table II - Derivative Security Cock Table II - Derivative Security Cock Table II - Derivative Security Conversion on Pate (Month/Day/Year) Table II - Derivative Security Conversion onversion onversion onversion onversion onversion onversion of Execution Date (Month/Day/Year) Table II - Derivative Security Code (Month/Day/Year)	Address of Reporting Person AGIOS AGIO (First) (Middle) SPHARMACEUTICALS, INC. YSTREET DGE MA 02139 (State) (Zip) Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) tock 1. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year)	Address of Reporting Person* Cott Cott	Address of Reporting Person (First) (Middle) SPHARMACEUTICALS, INC. Y STREET Table I - Non-Derivative Securities Acqueric (Month/Day/Year) Table I - Non-Derivative Securities Acqueric (Month/Day/Year) Table II - Derivative Securities Acqueric (Month/Day/Year) Transaction Code (Instr. 3) Transaction Date (Fransaction Derivative Securities Acqueric (A) or Disposed of (D) (Instr. 3, 4 and 5) Transaction Securities Acqueric (A) or Disposed of (D) (Instr. 3, 4 and 5) Transaction Securities Acqueric (A) or Disposed of (D) (Instr. 3, 4 and 5)	Address of Reporting Person Cott	Address of Reporting Person Cott (First) (Middle) S PHARMACEUTICALS, INC. Y STREET Table I - Non-Derivative Securities Acquired, Date (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (Instr. 3) A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) Solution Table II - Derivative Securities Acquired, Disposed of (Instr. 3) A. Deemed Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deemed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (A) or Disposed of (Instr. 3) A. Deamed Securities Acquired (Instr. 3) A. Deamed Securities Acquired (Instr. 3) A. Deamed Securities Acquired (Instr. 3) A	Address of Reporting Person Cott	Address of Reporting Person Cott	AGIOS PHARMACEUTICALS INC [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 9. SPHARMACEUTICALS, INC. Y STREET Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Incurity (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Instr. 3) 2. Transaction (Month/Day/Year) (Month/Day/Year)	Address of Reporting Person Cott	Address of Reporting Person Cott	AGIOS PHARMACEUTICALS INC AGIOS PHARMACEUTICALS INC AGIO S. PHARMACEUTICALS, INC Officer (give title below)	Address of Reporting Person Soft Address of Reporting Person AGIOS PHARMACEUTICALS INC AGIOS AGIOS PHARMACEUTICALS INC AGIOS A	2.	

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.
- 4. This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
- 5. This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

Remarks:

/s/ Andrew Hirsch, as Attorney-in-Fact for Scott Biller

** Signature of Reporting Person

 cott
 03/22/2017

 Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.